Abstract
Coadministration with the human immunodeficiency virus (HIV) protease inhibitor ritonavir was investigated as a method for enhancing the levels of other peptidomimetic HIV protease inhibitors in plasma. In rat and human liver microsomes, ritonavir potently inhibited the cytochrome P450 (CYP)-mediated metabolism of saquinavir, indinavir, nelfinavir, and VX-478. The structural features of ritonavir responsible for CYP binding and inhibition were examined. Coadministration of other protease inhibitors with ritonavir in rats and dogs produced elevated and sustained plasma drug levels 8 to 12 h after a single dose. Drug exposure in rats was elevated by 8- to 46-fold. A > 50-fold enhancement of the concentrations of saquinavir in plasma was observed in humans following a single codose of ritonavir (600 mg) and saquinavir (200 mg). These results indicate that ritonavir can favorably alter the pharmacokinetic profiles of other protease inhibitors. Combination regimens of ritonavir and other protease inhibitors may thus play a role in the treatment of HIV infection. Because of potentially substantial drug level increases, however, such combinations require further investigation to establish safe regimens for clinical use.
Full Text
The Full Text of this article is available as a PDF (108.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Coffin J. M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995 Jan 27;267(5197):483–489. doi: 10.1126/science.7824947. [DOI] [PubMed] [Google Scholar]
- Condra J. H., Schleif W. A., Blahy O. M., Gabryelski L. J., Graham D. J., Quintero J. C., Rhodes A., Robbins H. L., Roth E., Shivaprakash M. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995 Apr 6;374(6522):569–571. doi: 10.1038/374569a0. [DOI] [PubMed] [Google Scholar]
- Danner S. A., Carr A., Leonard J. M., Lehman L. M., Gudiol F., Gonzales J., Raventos A., Rubio R., Bouza E., Pintado V. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995 Dec 7;333(23):1528–1533. doi: 10.1056/NEJM199512073332303. [DOI] [PubMed] [Google Scholar]
- Dorsey B. D., Levin R. B., McDaniel S. L., Vacca J. P., Guare J. P., Darke P. L., Zugay J. A., Emini E. A., Schleif W. A., Quintero J. C. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem. 1994 Oct 14;37(21):3443–3451. doi: 10.1021/jm00047a001. [DOI] [PubMed] [Google Scholar]
- Greenberg R. N. Overview of patient compliance with medication dosing: a literature review. Clin Ther. 1984;6(5):592–599. [PubMed] [Google Scholar]
- Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995 Jan 12;373(6510):123–126. doi: 10.1038/373123a0. [DOI] [PubMed] [Google Scholar]
- Kempf D. J., Marsh K. C., Denissen J. F., McDonald E., Vasavanonda S., Flentge C. A., Green B. E., Fino L., Park C. H., Kong X. P. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2484–2488. doi: 10.1073/pnas.92.7.2484. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kempf D. J., Marsh K. C., Fino L. C., Bryant P., Craig-Kennard A., Sham H. L., Zhao C., Vasavanonda S., Kohlbrenner W. E., Wideburg N. E. Design of orally bioavailable, symmetry-based inhibitors of HIV protease. Bioorg Med Chem. 1994 Sep;2(9):847–858. doi: 10.1016/s0968-0896(00)82036-2. [DOI] [PubMed] [Google Scholar]
- Kempf D. J., Marsh K. C., Paul D. A., Knigge M. F., Norbeck D. W., Kohlbrenner W. E., Codacovi L., Vasavanonda S., Bryant P., Wang X. C. Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother. 1991 Nov;35(11):2209–2214. doi: 10.1128/aac.35.11.2209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Keogh A., Spratt P., McCosker C., Macdonald P., Mundy J., Kaan A. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med. 1995 Sep 7;333(10):628–633. doi: 10.1056/NEJM199509073331004. [DOI] [PubMed] [Google Scholar]
- Kronbach T., Fischer V., Meyer U. A. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther. 1988 Jun;43(6):630–635. doi: 10.1038/clpt.1988.87. [DOI] [PubMed] [Google Scholar]
- Kumar G. N., Rodrigues A. D., Buko A. M., Denissen J. F. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther. 1996 Apr;277(1):423–431. [PubMed] [Google Scholar]
- Markowitz M., Saag M., Powderly W. G., Hurley A. M., Hsu A., Valdes J. M., Henry D., Sattler F., La Marca A., Leonard J. M. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995 Dec 7;333(23):1534–1539. doi: 10.1056/NEJM199512073332204. [DOI] [PubMed] [Google Scholar]
- Molla A., Korneyeva M., Gao Q., Vasavanonda S., Schipper P. J., Mo H. M., Markowitz M., Chernyavskiy T., Niu P., Lyons N. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996 Jul;2(7):760–766. doi: 10.1038/nm0796-760. [DOI] [PubMed] [Google Scholar]
- Nedelcheva V., Gut I. P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica. 1994 Dec;24(12):1151–1175. doi: 10.3109/00498259409038673. [DOI] [PubMed] [Google Scholar]
- Perelson A. S., Neumann A. U., Markowitz M., Leonard J. M., Ho D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996 Mar 15;271(5255):1582–1586. doi: 10.1126/science.271.5255.1582. [DOI] [PubMed] [Google Scholar]
- Reedijk M., Boucher C. A., van Bommel T., Ho D. D., Tzeng T. B., Sereni D., Veyssier P., Jurriaans S., Granneman R., Hsu A. Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother. 1995 Jul;39(7):1559–1564. doi: 10.1128/aac.39.7.1559. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Roberts N. A., Martin J. A., Kinchington D., Broadhurst A. V., Craig J. C., Duncan I. B., Galpin S. A., Handa B. K., Kay J., Kröhn A. Rational design of peptide-based HIV proteinase inhibitors. Science. 1990 Apr 20;248(4953):358–361. doi: 10.1126/science.2183354. [DOI] [PubMed] [Google Scholar]
- Rodrigues A. D., Lewis D. F., Ioannides C., Parke D. V. Spectral and kinetic studies of the interaction of imidazole anti-fungal agents with microsomal cytochromes P-450. Xenobiotica. 1987 Nov;17(11):1315–1327. doi: 10.3109/00498258709047162. [DOI] [PubMed] [Google Scholar]
- Rodrigues A. D., Mulford D. J., Lee R. D., Surber B. W., Kukulka M. J., Ferrero J. L., Thomas S. B., Shet M. S., Estabrook R. W. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metab Dispos. 1995 Jul;23(7):765–775. [PubMed] [Google Scholar]
- Schapiro J. M., Winters M. A., Stewart F., Efron B., Norris J., Kozal M. J., Merigan T. C. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med. 1996 Jun 15;124(12):1039–1050. doi: 10.7326/0003-4819-124-12-199606150-00003. [DOI] [PubMed] [Google Scholar]
- Stein D. S., Fish D. G., Bilello J. A., Preston S. L., Martineau G. L., Drusano G. L. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS. 1996 May;10(5):485–492. doi: 10.1097/00002030-199605000-00006. [DOI] [PubMed] [Google Scholar]
- Vacca J. P., Dorsey B. D., Schleif W. A., Levin R. B., McDaniel S. L., Darke P. L., Zugay J., Quintero J. C., Blahy O. M., Roth E. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4096–4100. doi: 10.1073/pnas.91.9.4096. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vincent S. H., Karanam B. V., Painter S. K., Chiu S. H. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch Biochem Biophys. 1992 May 1;294(2):454–460. doi: 10.1016/0003-9861(92)90711-5. [DOI] [PubMed] [Google Scholar]
- Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995 Jan 12;373(6510):117–122. doi: 10.1038/373117a0. [DOI] [PubMed] [Google Scholar]